351 results about "Bile acid" patented technology

The invention discloses a leak-free core-shell hydrogel microsphere delivery system for non-contact flora transplantation as well as a construction method and application of the leak-free core-shell hydrogel microsphere delivery system. According to the invention, bacteria are encapsulated in a core of a core-shell microsphere through a two-step photo-initiation emulsion polymerization method of methacrylic acid gelatin, and a non-contact microbiota transplantation system (NMTS) is constructed. The NMTS can be used for biological encapsulation of various strains, shows encapsulation efficiency close to 100%, and has little influence on bacterial activity at the same time. NMTS demonstrates: a shielding effect that protects sealed bacteria from low pH values in the gastrointestinal tract and bile acid disruption; sufficient mechanical strength ensures that bacterial leakage is prevented and the infection risk is eliminated in the whole gastrointestinal tract delivery process; and internal and external substance exchange is realized, and the intestinal microorganism structure is remodeled. The invention provides a unique bacterial cell microencapsulation method which is a non-contact, safe and effective micropopulation transplantation method.

The present invention discloses a Lactobacillus plantarum and its application in the preparation of functional preparations for preventing and treating inflammatory bowel disease, as well as antioxidant, anti-inflammatory and antibacterial functions. It has excellent ability to scavenge reactive oxygen species, as well as good probiotic characteristics such as acid tolerance, bile salt tolerance, hydrophobicity, self-aggregation ability and inhibition of common human pathogenic bacteria. At the same time, it can improve intestinal inflammation, has a preventive and therapeutic effect on inflammatory bowel disease, and has high biological safety. It can be used as a probiotic preparation to relieve inflammatory bowel disease, improve intestinal mucosal damage and colon inflammation, providing a new strategy for the prevention and treatment of inflammatory bowel disease and having potential clinical application prospects.

The invention belongs to but is not limited to the technical field of biomedicine, and discloses application of golden amide alcohol ester to preparation of a medicine for treating cholestasis. The in-vitro cell level verifies that the golden amide alcohol ester has relatively strong activity of activating FXR and CAR. The golden amide alcohol ester can relieve the cholestasis symptom of a cholestasis model mouse. The golden amide alcohol ester can obviously reduce the content of total bile acid and bilirubin in cells, relieve cholestasis and relieve hepatocyte damage. The golden amide alcohol ester can regulate and control the protein level of transporters and metabolic enzymes related to bile acid and bilirubin through double excitation of FXR and CAR, relieve cholestasis and achieve the purposes of benefiting gallbladder and removing jaundice.

The invention relates to application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of a medicine for resisting cholestatic liver diseases, and belongs to the technical field of medicinal chemistry. The 1, 2, 3, 4, 6-O-pentagalloylglucose provided by the invention can be used for promoting bile acid excretion by reducing WDR6 protein expression. In-vivo and in-vitro experiments prove that the 1, 2, 3, 4, 6-O-pentagalloylglucose can be used for remarkably relieving the symptom of the cholestatic liver disease. In addition, the 1, 2, 3, 4, 6-O-pentagalloylglucose has no obvious toxic or side effect, and has no obvious influence on the liver function and the kidney function. The 1, 2, 3, 4, 6-O-pentagalloylglucose has a wide anti-cholestatic liver disease spectrum, and is suitable for various cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and the like.

The invention discloses interference engineering bacteria for blocking early infection of animal parasitic nematodes and application, and belongs to the field of animal parasitic disease prevention and treatment. According to the interference engineering bacteria disclosed by the invention, the HCON00038080 (cyp-22a1) gene of haemonchus contortus is specifically silenced by expressing double-stranded RNA (dsRNA), so that the biosynthesis of endogenous bile acid-like steroid hormone of the haemonchus contortus is inhibited, the activation of infectious larvae is influenced, and the infection establishment process of the infectious larvae is blocked. The invention can be used for preventing early infection of haemonchus disease of ruminants such as cattle, sheep, camels and the like and the phenomenon of spring / perinatal high tide, has higher application value for prevention and control of haemonchus disease, and has reference value for prevention and control of parasitic nematode disease of other animals.

The invention belongs to the technical field of feed additives, and particularly relates to slow-release fat powder for pigs and a preparation method of the slow-release fat powder. The slow-release fat powder for pigs comprises an intragastric adhesion-slow release layer, a small intestine forepart bile acid response controlled release layer and a small intestine posterior microbe response controlled release layer. The prepared slow-release fat powder for the pigs is good in stability, accurate release of different nutritional ingredients in different parts of gastrointestinal tracts of the pigs can be achieved, and powerful support is provided for sustainable development of the pig raising industry.

The invention provides a metal organic framework composite adsorbent, a preparation method thereof and a hemoperfusion device, and belongs to the technical field of blood purification adsorption materials. The metal organic framework composite adsorbent provided by the invention is a metal organic framework material-polysulfone material composite sphere, the metal organic framework material has excellent adsorbability to various toxins, and the polysulfone material has good biocompatibility, mechanical strength, processing adaptability and sterilization capability; therefore, the metal organic framework composite adsorbent has good blood compatibility and toxin adsorbability, is less in adsorbent particle falling, and is suitable for the field of whole blood perfusion. The result of the embodiment shows that the metal organic framework composite adsorbent provided by the invention has excellent adsorption performance on p-cresol sulfate, indoleacetic acid, bilirubin, bile acid and endotoxin, and shows excellent blood compatibility.

The invention relates to a poria cocos extract and a preparation process thereof. According to the invention, ethanol and N-methyl pyrrolidone are used as extraction solvents to prepare the poria cocos extract, and the extract is rich in poria cocos triterpenes and polysaccharides. Experimental results show that the obtained extract has a remarkable treatment effect on gall-stone model mice, the number of cholesterol crystals in gallbladders of the mice can be remarkably reduced, the content of cholesterol in the gallbladders can be reduced, and the content of phospholipid and bile acid in the gallbladders can be effectively increased.

The invention provides a water-blocking microcapsule, a fish oil composite hair beautifying ointment and a preparation method, and relates to the technical field of animal health products. The water-blocking microcapsule is a solid particle formed by a core material and a wall material coating the core material; the core material is fish oil emulsion subjected to bile salt emulsification treatment; the wall material sequentially comprises an inner-layer wall material and an outer-layer wall material from inside to outside; the inner-layer wall material is a wall material formed by solidifying alginate; and the outer-layer wall material is a water-blocking wall material which is arranged outside the inner-layer wall material and is made of nanocrystalline cellulose. The water-blocking microcapsule provided by the invention realizes multiple beneficial effects of efficient digestion and absorption of fish oil, improvement of palatability, enhancement of oxidation resistance and stability, fixed-point release of intestinal tracts and the like, provides an innovative technical scheme for development of animal health products, and has wide application prospects and market values.

The invention discloses emblic leafflower fruit polysaccharide with sugar-controlling and lipid-lowering activity as well as a preparation method and application of the emblic leafflower fruit polysaccharide. The polysaccharide is prepared by taking fresh phyllanthus emblica pulp as a raw material through hot water extraction, yeast fermentation, desorption after XAD-16 macroporous resin adsorption, alcohol precipitation, ultrafiltration and DEAE-52 cellulose column purification. The low-molecular-weight gulcomannan is separated from phyllanthus emblica for the first time, and monosaccharide composition of the gulcomannan mainly comprises glucose, mannose and galactose and contains trace rhamnose and xylose. The polysaccharide has sugar-controlling and lipid-lowering active action targets in the whole digestive tract (the upper digestive tract: glycolipid digestion and absorption enzymes alpha-amylase, alpha-glucosidase and pancreatic lipase inhibitory activity, starch hydrolysis delay, bile acid adsorption capacity and cholesterol micelle dissolution inhibition capacity; in the lower digestive tract, the multiplication promoting capacity of glycolipid metabolism-related probiotics) shows extremely high biological activity, and can be applied to food and health care products.

The invention discloses lactobacillus plantarum YBE2 and application thereof.According to the lactobacillus plantarum YBE2 for high yield of extracellular polysaccharide mainly containing rhamnose, different cholate types can be degraded at the same time, glycocholic acid is specifically hydrolyzed, and the lactobacillus plantarum YBE2 has the effects of lowering cholesterol and relieving acute inflammation at the same time. Meanwhile, the plant lactobacillus YBE2 can reduce the deposition of fat in the belly of the cage rearing broiler chicken, improve intramuscular fat, promote the deposition of fatty acid in muscles, reduce the total bile acid of plasma, triglyceride and low-density lipoprotein cholesterol, and remarkably improve the lipid metabolism and muscle quality of meat poultry, and can be widely applied to the breeding of the cage rearing broiler chicken, promote the healthy breeding of the meat poultry and improve the quality of the meat poultry. The culture benefit is improved.

Provided herein are methods and compositions for treating a neurodegenerative disease (e.g., AD or PSP). The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.

The invention discloses Pediococcus pentosaceus G41, which is separated from rumen fluid of healthy adult dairy cows in a certain cattle farm in Changchun, has the advantages of high growth speed and strong acid production capacity, and can effectively relieve cholestatic liver injury. Experiments prove that the Pediococcus pentosaceus G41 reduces the activity of serum AST, ALT and GDH of a mouse with cholestatic liver injury, reduces the content of total bile acid in blood and liver, increases the content of total bile acid in excrement, and improves cholestatic and dirty injury caused by cholestatic.

The invention relates to a composition for treating large yellow croaker pyramidoniasis as well as a preparation method and application thereof, and belongs to the technical field of aquaculture. The composition comprises the following components: curcumin, bile acid, beta glucan, bacillus subtilis freeze-dried powder, marine red yeast freeze-dried powder, vitamin C, vitamin E and ethylicin. When the feed additive is added into basal feed to feed large yellow croakers infected with the trypanosomiasis, the death rate of sick fishes can be effectively reduced, the polypide loading capacity is remarkably reduced, and pathological injuries of livers and spleens of the large yellow croakers are relieved. In addition, the composition can also improve the non-specific immunity of the fish body, improve the liver function, enhance the antioxidant capacity of the liver, and improve the lipase activity of the intestinal tract at the same time. Therefore, the composition can be used as a medicine or a feed additive for treating the large yellow croaker pyramidoniasis, has the advantages of small dosage and remarkable effect, and provides a new technical approach for solving the problem that the current large yellow croaker pyramidoniasis lacks an effective prevention and control means.

A method of evaluating disposition and / or effect of a candidate compound in an in vitro culture and / or suspension to predict in vivo disposition and / or effect of the candidate compound, which can include the steps of providing a cell culture and / or suspension; exposing a candidate compound to the culture and / or suspension; exposing the culture and / or suspension to a media providing an in vivo relevant extracellular environment, such as a media comprising a component (such as a protein and / or other component, such as lipoproteins, bile acids, and endogenous compounds such as bilirubin) at a physiologic concentration or a concentration having characteristics, such as binding characteristics, similar to the physiological concentration; wherein any combination of any of the exposing steps can occur in any order or simultaneously; and evaluating in vitro disposition and / or effect of the compound to predict in vivo disposition and / or effect of the candidate compound.

The invention relates to a compound preparation for improving the physique of weak stiff livestock. Every 100 ml of the compound preparation mainly comprises the following components according to a ratio: 0.1 to 0.3 g of vitamin E, 1 to 3 g of lactobacillus, 1 to 2 g of bile acid, 1 to 3 g of xylanase, 0.2 to 0.4 g of vitamin B1, 0.2 to 0.4 g of vitamin B2, 0.2 to 0.4 g of vitamin B6, 0.2 to 0.4 g of vitamin B12, 1 to 3 g of nicotinamide, 0.5 to 1.0 g of butafosfan, 1 to 3 g of taurine, 1 to 3 g of lysine, 0.5 to 1.0 g of levamisole hydrochloride, 5 g of soybean oil, 50 g of gelatin liquid, 5 to 10 ml of sodium sulfate solution, 1 to 2 g of Pickering emulsifier, 3 to 5 g of liquid paraffin and 1 to 2 g of Tween-80. The compound preparation not only pays attention to nutritional supplement, but also pays attention to regulation of an immune system and improvement of intestinal flora balance, so that the physique of the weak stiff livestock is comprehensively improved, and powerful support is provided for efficient development of the breeding industry.

The invention discloses a Min pig source lactobacillus reuteri LRM2293 strain and an application of the Min pig source lactobacillus reuteri LRM2293 strain in anti-inflammatory reaction. The Min pig source lactobacillus reuteri is named as Lactobacillus reuteri LRM2293, and is preserved in the China Center for Type Culture Collection, the address is Wuhan University, Wuhan, China, the preservation number is CCTCC NO: M 20242331, and the preservation time is October 25, 2024. Research finds that the lactobacillus reuteri LRM2293 has the capacity of transforming bile acid in vitro and can be used as a candidate strain of probiotics. In vitro, a culture supernatant of the lactobacillus reuteri LRM2293 can be used for reducing the inflammatory reaction of IPEC-J2 cells; in vivo, the LRM2293 strain can be colonized in each intestinal segment of a piglet, and can repair an intestinal barrier and relieve intestinal injury of the inflammatory piglet, so that the problem of antibacterial drug resistance caused by abuse of antibiotics is expected to be reduced, and a technical means is provided for development of a novel functional product.

The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C14-24 fatty acids, one or more free C14-24 fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions.

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

The invention relates to the technical field of aquaculture, in particular to a preparation method and application of seawater larval fish biological bait. The preparation method comprises the following steps: mixing schizochytrium limacinum powder, bile acid and sunflower phospholipid according to a mass ratio of 50: (10-20): (10-20) to obtain the nutrition enhancer; diluting the nutrition enhancer until the concentration is 40g / t-50g / t, so as to obtain a diluent; adding 130-150 common rotifers into each milliliter of diluent, culturing for 12-18 hours, and collecting strengthened rotifers; 30-50 common artemia is added into each milliliter of the diluent, culturing is carried out for 12-18 hours, and reinforced artemia is collected; the combination of the strengthened rotifer and the strengthened artemia is the larval fish biological bait. The larval fish biological bait prepared by the invention is uniform in fry specification and high in survival rate in a bait transfer period, and has remarkable economic and ecological benefits.

The present invention relates to the application of saliva combined with lactobacillus in the preparation of a drug for treating obesity, and belongs to the field of biomedicine technology. The present invention provides the application of saliva combined with lactobacillus XA-1416 in the preparation of a drug for preventing and / or treating obesity, or preventing and / or treating obesity-related diseases. This strain can inhibit the weight gain of mice with obesity model induced by high-fat diet, reduce the blood lipid level of mice with obesity model induced by high-fat diet, improve the liver damage index of mice with obesity model induced by high-fat diet, reduce the area of ​​white fat cells in mice with obesity model induced by high-fat diet, promote the conversion of intestinal conjugated bile acid to free bile acid in mice with obesity model induced by high-fat diet, increase the level of intestinal FXR antagonist in mice with obesity model induced by high-fat diet, improve the intestinal flora imbalance of mice with obesity model induced by high-fat diet, inhibit fat accumulation in Hep G2 model, and inhibit differentiation into adipocytes in 3T3-L1 model.

The invention discloses an active tuberculosis diagnosis method based on proteomics and metabonomics. The method comprises the following steps: collecting a serum sample of a suspected active tuberculosis patient; detecting specific proteins in the serum sample by using a proteomics technology; detecting specific amino acids in the serum sample by using a metabonomics technology; carrying out standardization treatment on the obtained protein, amino acid and bile acid data; establishing a diagnosis model by using a machine learning algorithm; inputting data of a to-be-diagnosed sample into the model, and calculating a probability value of the to-be-diagnosed sample suffering from active tuberculosis; according to a preset threshold value, whether the sample provider suffers from the active tuberculosis or not is judged. By comprehensively analyzing multiple omics data, the sensitivity and specificity of diagnosis are greatly improved; by utilizing a machine learning algorithm, the disease risk can be objectively and quantitatively evaluated, and human misjudgment is reduced; the detection process is simple and fast, the sample demand is small, and clinical popularization and application are facilitated.

The invention belongs to the technical field of disease medicine preparation, and particularly relates to nanocellulose, a preparation method thereof and application of the nanocellulose to reduction of bile acid level. The nano-crystalline cellulose is nano-crystalline cellulose fiber or nano-crystalline cellulose crystal; wherein the nano-crystalline cellulose fibers are in a slender whisker shape, the average length of the nano-crystalline cellulose fibers is 250-400 nm, and the nano-crystalline cellulose fibers are partially gathered and wound; the nanocellulose crystal is in a short rod crystal shape, the surface of the nanocellulose crystal is connected with a sulfuric acid half ester group, and the length of the nanocellulose crystal is 50-200 nm. The nanocellulose provided by the invention can achieve the purpose of treating intrahepatic cholestasis in the gestation period by improving the TBA level and improving the filial generation live birth rate; the traditional Chinese medicine composition has no obvious influence on liver and kidney functions, blood sugar, blood fat and the like, and is high in safety; in addition, the nanocellulose does not have potential target organ poison or accumulative effect, the biological safety performance is improved, and the nanocellulose can be used for a long time and is suitable for special crowds during pregnancy.

The invention belongs to the technical field of fermentation and metagen preparations, and particularly relates to application of bifidobacterium breve metagen in the aspects of scavenging free radicals and relieving oxidative aging. According to the present invention, the oxidative free radical scavenging experiment results show that the bifidobacterium breve NKU BB 1-2 metagen has good oxidative free radical scavenging ability, and has good scavenging ability on hydroxyl free radicals, superoxide anions and DPPH free radicals; meanwhile, through component analysis, it is found that the bifidobacterium breve NKU BB 1-2 metagen contains various antioxidant and anti-aging bioactive substances such as flavonoids, indoles, amino acids, bile acids and ceramides; a cell model experiment verifies that the bifidobacterium breve NKU BB 1-2 metagen can obviously relieve oxidative damage to the cells and improve the oxidation resistance of the cells, so that oxidative aging is relieved.

The invention belongs to the technical field of biological medicine, and discloses a dry blood spot liquid chromatography-mass spectrometry detection method adaptive to 7 metabolites. According to the method, a pH / polarity double-trigger microcapsule solvent carrier system is adopted, high-polarity extraction solvents, medium-polarity extraction solvents and low-polarity extraction solvents are packaged in the pH / polarity double-trigger microcapsule solvent carrier system in a layered mode, the solvents are released in sequence according to local pH and polarity changes in the extraction process, and amino acid, acyl carnitine, organic acid, bile acid, steroid, fatty acid and glycometabolism intermediate products are efficiently extracted respectively. The method disclosed by the invention breaks through the inherent limitation of a traditional static solvent system, solves the problem of unbalanced recovery rate caused by insufficient solvent suitability in dry blood spot extraction of seven metabolites with great polarity span, and remarkably improves the accuracy, reproducibility and coverage range of a DBS-LC-MS / MS platform in synchronous detection of multi-component metabolites; and reliable technical support is provided for newborn inherited metabolic disease screening, endocrine disease diagnosis and drug metabolism research.

This invention belongs to the field of bile acid detection technology, and discloses a sample pretreatment method for determining the content of bile acid subtypes and its application. The pretreatment method includes the following steps: S1, acidifying the sample to be tested with an acidifying agent to a pH of 2-4 to obtain an acidified sample; S2, eluting the acidified sample onto a mixed-mode anion exchange column to obtain an eluent; S3, evaporating the eluent and reconstituted with a rehydration solution to obtain the test sample. The test sample obtained by this pretreatment method can effectively eliminate or compensate for matrix interference when used for targeted analysis of bile acid subtypes by LC-MS / MS, thus effectively improving detection sensitivity.

The invention relates to the technical field of aquaculture feed, and provides a compound feed additive for improving fish sugar utilization rate and promoting growth, the compound feed additive comprises the following raw materials by weight: 0.1-0.14 part of chromium picolinate, 1.5-2.5 parts of vitamin C, 20-40 parts of amylase, 20-40 parts of protease, 10-20 parts of dimethyl-beta-propiothetin, 2-4 parts of bile acid, and 18-22 parts of a carrier. The compound feed additive provided by the invention has the beneficial effects that the blood sugar is regulated, and the sugar metabolism capability of fish bodies is improved; due to the use of the compound feed additive, energy supply caused by protein decomposition is reduced, so that the growth performance of the fishes and the utilization rate of the feed are improved; the low-temperature stress resistance of the fishes is improved, and the breeding negative influence caused by temperature change is reduced; the protein loss is reduced; the feed cost is reduced; and the culture benefit is improved.

The present invention provides means with which bile acids, phenols, indoles and organic acids contained in a sample can be stably preserved without cryopreservation of the sample. A sample preservation solution of the present invention is a sample preservation solution used for analyzing at least one component selected from the group consisting of bile acids, phenols, indoles and organic acids contained in a biological or environmental sample, containing at least the following (A) and (B): (A) condensed phosphate or polyoxyethylene sorbitan alkylate; and (B) guanidinium thiocyanate, Tris-HCl (pH 7 to 9), and EDTA.

The application relates to the technical field of medical detection, in particular to a detection kit for total bile acid and a detection kit for total bile acid. The application adds polyoxyethylene-polyoxypropylene copolymer, Span 40 and oxide in R1, and adds EDTA-Na2 and sodium bicarbonate in R2, so that the stability and precision of reagents are effectively improved, and the situation that a negative value is generated in the detection process is solved.